Summary The FHIT gene, recently cloned and mapped on chromosome 3p14.2, has frequently been found to be abnormal in several established cancer cell lines and primary tumours. As alterations of chromosome 3p are common events in ovarian cancers with breakpoint sites at 3p14.2, we decided to investigate the role of FHIT in human ovarian tumorigenesis. Fifty-four primary ovarian carcinomas were studied by reverse transcription of FHITmRNA followed by polymerase chain reaction (PCR) amplification and sequencing of products. The same tumours and matched normal tissues were also investigated for loss of heterozygosity using three microsatellite markers located inside the gene. We found an abnormal transcript of the FHIT gene in two cases (4%) and allelic losses in eight cases (15%). Twelve (22%) of the 54 tumours investigated belonged to young patients with a family history of breast/ovarian cancer. In none of these cases was the FH/Tgene found to be altered. Our results indicate that FH/T plays a role in a small proportion of ovarian carcinomas.
Ovarian cancer represents the most frequent cause of death for gynaecological malignancies in the Western world (Shelling et al, 1995) . In fact, after primary surgery, the overall 5-year survival is still very low, mainly because of lack of improvement in early diagnosis and particular aggressiveness of the disease (Chang et al, 1994) . As the genetic background of neoplastic cells may determine their biological behaviour, several studies have been focused on the analysis of genomic loci subjected to allelic losses on different chromosomes to identify potential tumour-suppressor genes in ovarian cancer (Eccles et al, 1990 ; Russel et al, 1990; Cliby et al, 1993; Osborne and Leech, 1994) . Complex cytogenetic abnormalities have been demonstrated in ovarian carcinomas; some of them seem to be non-random (Islam et al, 1993; , including loss of heterozygosity (LOH) at chromosome 3p (Ehlen and Dubeau, 1990; Zheng et al, 1991; Leary et al, 1993) . Recently, the FHIT gene has been identified by an exon-trapping strategy in cancer cell lines with homozygous deletions at region 3pl4.2 . FHIT is a highly conserved gene composed of ten exons distributed over approximately 1 Mb of genomic DNA, with three untranslated exons. This gene encompasses the FRA3B, an aphidicolin inducible fragile site and the site of t(3;8) translocation breakpoint of familiar renal cell carcinoma . The FHIT protein shows a high homology to the yeast Schizosaccharomyces pombe diadenosine tetraphosphate hydrolase (Huang et al, 1995) . This similarity suggests that the FHIT protein may have hydrolase activity and might cleave the diadenosine 5',5"-P',P4-tetraphosphate (Ap4A), a molecule involved in DNA replication and cell cycle control (Barnes et al, 1996) . It has also been demonstrated that the introduction of chromosome 3pl4-p12 into renal carcinoma cells with a t(3;8) translocation in that region resulted in partial suppression of tumour growth (Sanchez et al, 1994) . These data strongly suggest that the FHIT gene is a putative tumour suppressor. Abnormalities of the FHIT locus were found in several established cancer cell lines and in primary resected tumours, including lung, breast, oesophagus, stomach and pancreas carcinomas Negrini et al, 1996; Shridhar et al, 1996; Sozzi et al, 1996a and b; Thiagalingam et al, 1996) .
In 
Allelic losses analysis
DNAs from frozen tumours and matching normal tissues were extracted using standard protocols (Sambrook et al, 1989) . Analysis of allelic losses of the FHIT gene was performed on tumours and matching normal ovarian tissues using a polymerase chain reaction (PCR)-based method using, for each case, three microsatellite markers (D3S4103, D3S1300 and D3S1234) Ohta et al, 1996) , all internal to the FHIT gene. D3S 1300 and D3S4103 markers are located in the epicentre of the fragile region encompassing exon 5 of the FHIT gene and D3S 1234 is located distally in the intron 8, at the 3' end of the gene. An additional microsatellite marker, D3S 1271, located at chromosomal band 3p1 .2 was used as control for LOH outside the FHIT gene. The sequences of all primers used can be obtained through the genome database. Routinely, 100 ng of genomic DNA was used in a 10-gl PCR reaction containing 10 mM Tris-HCI (pH 8.3), 1.5 mm magnesium chloride, 50 mM potassium chloride, 0.01% (w/v) gelatine, 1.25 mm each of four dNTPs (Boehringer Mannheim Biochemica), 1 mm of each primer, 0.5,l of [a-32P]dCTP (3000 Ci mmol-', Amersham, Arlington, IL, USA) and 0.25 units of Taq DNA polymerase (Perkin-Elmer Cetus, Norwalk, CT, USA). The PCR reaction was programmed as follows: initial denaturation, 5 min at 94'C; amplification, 30 s at 94°C, 30 s at 57-60°C, 30 s at 72°C for 20 cycles; elongation, 10 min at 72°C. PCR products were processed by the addition of 5 tl of loading buffer consisting of 98% formamide, 1% EDTA (pH 8.0), 0.03% xylene cyanol and 0.03% bromophenol blue. The reaction was denatured at 95°C for 5 min. An aliquot of 5 ,l was loaded onto a 6% urea-polyacrylamide gel for 2-3 h at 55 W. The gels were dried and exposed against a Kodak XAR-5 film at -80°C. For informative cases, allelic loss was scored if the autoradiographic signal of one allele was approximately 50% reduced in the tumour DNA compared with the corresponding normal allele. (Figure 1) . In tumour no. 48 and in one other neoplastic sample (case no. 39), with a normally sized message, a smaller band, presumably corresponding to an altered transcript, was seen (Figure 1 ). In these two cases, the matched non-neoplastic tissues showed only the normal FHIT message.
Sequence analysis of the major RT-PCR product was performed. The results revealed a full-length size FHIT transcript. Sequence analysis of abnormally sized transcripts showed a loss of exons 5-8 (nucleotides -17-348) in tumour no. 48 and a loss of exons 5 and 6 (nucleotides -17-249) in tumour no. 39 (Table 1) . Therefore, based on RT-PCR analysis, only 4% (2 of 54) of the ovarian carcinomas showed a FHIT alteration.
The same tumours and matched normal tissues were also investigated for LOH at D3S1300, D3S4103 and D3S1234 microsatellite-containing loci. The normal tissues of all samples were heterozygous for at least one of these markers.
We found LOH affecting at least one locus in 7 of 54 (13%) ovarian carcinomas (Figures 2 and 3) . These seven cases included one of the two tumours showing an abnormal transcript (case no. 39). Tumour DNA from sample no. 48 was not amplifiable with any of the couples of primers for microsatellite-containing sites located within the FHIT gene, indicating a homozygous deletion of the FHIT locus (data not shown). In order to demonstrate that the results obtained for tumour sample no. 48 were not because of quality of DNA, the same sample was subjected to PCR amplification of exon 5 of the p53 gene as previously described (Marchetti 
DISCUSSION
It has been assumed that ovarian cancer, as well as other neoplastic diseases, develops and progresses after the accumulation of a critical number of mutations within regulatory genes (Shelling et al, 1995) . With the exception of the p53 gene, which is mutated in most of the aggressive ovarian carcinomas (Bosari et al, 1993; Kupryjancyk et al, 1993; Buttitta et al, 1997) , other tumoursuppressor genes and oncogenes are infrequently altered in ovarian neoplasms.
It is known that the majority of epithelial ovarian cancers appear to be aneuploid and contain a variety of structural chromosomal abnormalities Islam et al, 1993; Shelling et al, 1995) , including LOH at many loci that could contain tumoursuppressor genes (Thompson et al, 1994) . Several studies have demonstrated allelic losses at chromosome 3p in different human carcinomas, including ovarian cancer (Ehlen and Dubeau, 1990; Zheng et al, 1991; Jones and Nakamura, 1992; Leary et al, 1993) . The putative tumour-suppressor FHIT gene has been recently cloned and localized on the short arm of chromosome 3. Recent data have shown FHIT gene abnormalities in a variety of cancerderived cell lines, as well as in primary tumours. In particular, aberrant transcripts of the FHIT locus were found in 80% of smallcell lung cancers (Sozzi et al, 1996a) and in 40% of non-small-cell lung cancers (Sozzi et al, 1996a) , in 50% of oesophageal and stomach tumours and in 30% of breast carcinomas . Discordant results have been reported in colorectal tumours Thiagalingam et al, 1996) . Despite the high frequency of chromosome 3p aberrations reported in ovarian malignancies, in the present study, we were able to find allelic losses of the FHIT locus in 15% (8 of 54 cases) of epithelial ovarian tumours and an aberrant FHIT transcript in only 4% (2 of 54 cases). These abnormal transcripts lack exon 5, which contains in-frame ATG start codons, therefore the FHIT protein encoded in these cases is unlikely to have functional properties.
In our study, to minimize contamination with nucleic acids derived from non-neoplastic cells, which could lead to ambiguous interpretation of data, only samples with a high proportion of neoplastic cells were subjected to genetic analysis. However, we cannot exclude the presence of a very small amount of normal cells in our samples and therefore a possible underestimation of allelic losses. On the other hand, in order to reduce the possibility of an overestimation of allelic losses, we avoided a nested-PCR strategy, which is more prone to false-positive results.
The inducible fragile site FRA3B contained within the FHIT locus could make this region susceptible to some form of neoplasticspecific instability. Therefore, it has been argued that losses of genetic material in the FHIT locus may be not related to tumorigenesis and that the FHIT gene does not represent a true gene target for cancer development (Thiagalingam et al, 1996) . The absence of LOH at the locus D3S 1271, located outside the FHIT gene, suggests that the observed chromosomal losses are specific for the FHIT gene. However, additional 3p markers have to be investigated to delineate the extent of chromosomal losses and to clarify this point.
Ovarian carcinomas are among the tumours with the highest number of chromosomal aberrations. The low frequency of FHIT alterations in such neoplasms strongly suggests that the FHIT abnormalities do not occur randomly, as a consequence of genetic instability, and they could exert a prominent aetiological role in specific tumour types. In fact, the FHIT gene appears to be involved particularly in tumours, such as small-and non-small-cell lung cancers, directly associated with the effects of agents present in tobacco smoke that interfere with DNA replication and repair. On the other hand, ovarian carcinomas seem to be not related to carcinogens, as suggested by recent observations indicating that p53 mutations in ovarian cancer are mostly (72%) G:C to A:T transitions occurring at CpG nucleotides (Shelling et al, 1995) . Such mutations are assumed to result from spontaneous deamination of 5-methylcytosine because of spontaneous errors in DNA synthesis, rather than direct interaction with carcinogens.
However, the possibility that, in ovarian tumorigenesis, the FHIT message may be affected at translational or post-translational levels can not be ruled out at present. Future studies on FHIT protein expression will clarify this point.
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Finally, the majority of ovarian carcinomas are sporadic and arise in peri-to post-menopausal age, while 10% of the cases are hereditary and develop in young patients (Houlston et al, 1991) . To investigate the potential role of FHIT in sporadic and familiar ovarian carcinomas, we included in this study 12 tumours developed in young women with a family history of breast/ovarian cancer. In no case, did we find any alteration in the FHIT locus.
Although limited to a low number of tumours, our results suggest that the FHIT gene is not involved in the development of hereditary ovarian cancer.
In conclusion, our results indicate that FHIT plays a role in a small proportion of ovarian carcinomas.
